Literature DB >> 25088300

A review of disease activity measures for psoriatic arthritis: what is the best approach?

Minyoung Her1, Arthur Kavanaugh.   

Abstract

The measuring tools for disease activity of rheumatoid arthritis have long been adapted for assessing the disease activity of psoriatic arthritis (PsA), particularly as regards peripheral arthritis. However, because of the multifactorial aspects and multiple domains of PsA, such as axial and peripheral joints, skin and nails, enthesitis and dactylitis, must also be considered when measuring activity. After the introduction of biologic agents, it became clear that more objective measuring tools were needed to assess the varied aspects of disease activity, as well as the effect of treatment. Collaborations among international groups of rheumatologists and dermatologists have helped define key or core domains of PsA that were recommended for inclusion in clinical trials and potentially clinical practice. Groups such as the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis have tried to develop and validate new outcome measures in PsA. Several new composite measures for specific PsA have been recently developed. The domains, instruments and traditional and new composite measures for PsA are reviewed herein.

Entities:  

Keywords:  assessment; composite score; disease activity; domain; outcome measure; psoriatic arthritis

Mesh:

Substances:

Year:  2014        PMID: 25088300     DOI: 10.1586/1744666X.2014.943663

Source DB:  PubMed          Journal:  Expert Rev Clin Immunol        ISSN: 1744-666X            Impact factor:   4.473


  4 in total

Review 1.  Making the next steps in psoriatic arthritis management: current status and future directions.

Authors:  Diviya Sritheran; Ying Ying Leung
Journal:  Ther Adv Musculoskelet Dis       Date:  2015-10       Impact factor: 5.346

2.  Site-specific resolution of enthesitis in patients with axial spondyloarthritis treated with tumor necrosis factor inhibitors.

Authors:  Michael J Nissen; Burkhard Möller; Adrian Ciurea; Ruediger B Mueller; Patrick Zueger; Martin Schulz; Fabiana Ganz; Almut Scherer; Eleftherios Papagiannoulis; Thomas Hügle
Journal:  Arthritis Res Ther       Date:  2021-06-09       Impact factor: 5.156

3.  Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study.

Authors:  L C Coates; D D Gladman; P Nash; O FitzGerald; A Kavanaugh; T K Kvien; L Gossec; V Strand; L Rasouliyan; L Pricop; K Ding; S M Jugl; C Gaillez
Journal:  Arthritis Res Ther       Date:  2018-12-07       Impact factor: 5.156

4.  The Role of Ultrasound in Assessing Hand Joints and Tendons in Psoriatic Arthritis.

Authors:  A Florescu; A E Mușetescu; L M Florescu; A Bondari; P L Ciurea; C C Vere; A M Bumbea
Journal:  Curr Health Sci J       Date:  2019-06-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.